IRD vs OCGN: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. IRD and OCGN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined IRD and OCGN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Opus Genetics develops treatments for eye disease, and it does so along two tracks that have very little to do with each other. The first is a portfolio of AAV gene therapies for inherited retinal diseases, which is where the ticker comes from: IRD is the industry abbreviation for inherited retinal disease. The lead program, OPGx-LCA5, is in a registrational Phase 3 trial for LCA5-associated blindness and carries FDA Rare Pediatric Disease, Orphan Drug and RMAT designations. Behind it sit OPGx-BEST1 for bestrophin-1 related retinal disease, plus earlier programs targeting RDH12, MERTK, RHO, CNGB1 and NMNAT1. The second track is phentolamine ophthalmic solution 0.75%, which is already FDA-approved and sold by Viatris as RYZUMVI for reversing dilated pupils after an eye exam, and which is under FDA review for a much larger presbyopia indication with a target action date of October 17, 2026. The company was formed when Ocuphire Pharma acquired the private Opus Genetics in late 2024 and took its name, which is why the SEC filer history runs back through Ocuphire and Rexahn.

Full IRD guide

Ocugen, Inc. is a clinical-stage biotechnology company headquartered in Malvern, Pennsylvania, focused on gene and cell therapies for eye diseases. Its core asset is a modifier gene-therapy platform that uses nuclear hormone receptor genes to address disease across many genetic mutations rather than one at a time. The lead program, OCU400, targets broad retinitis pigmentosa in the Phase 3 liMeliGhT trial; OCU410 targets geographic atrophy secondary to dry age-related macular degeneration; and OCU410ST targets Stargardt disease. The company has framed a goal of pursuing three biologics license applications across these programs and also runs earlier-stage work in other modalities.

Full OCGN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• IRD drivers: The presbyopia decision on October 17, 2026; OPGx-LCA5 is in a registrational trial with a defined path.
• OCGN drivers: Lead program advancing toward a regulatory decision; A platform, not a single shot on goal.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The trailing numbers do not support the valuation on any conventional measure, so essentially all of the market capitalization rests on events that have not happened yet. For OCGN, ocugen is a speculative, clinical-stage company with no approved products and no meaningful product revenue, so its programs may fail in trials or fall short of regulatory approval.

Pick IRD if you believe its drivers more; OCGN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the IRD and OCGN guides.

IRD. No revenue multiple is informative here, because the roughly $9.9 million trailing figure is a development-cost reimbursement that shrinks as programs complete, not a commercial ramp. What the market is pricing instead is the presbyopia royalty stream if the October 2026 sNDA clears, the LCA5 Phase 3 asset, and the newly de-risked BEST1 program, against roughly 83 million shares and a balance sheet that does not force a near-term raise. Sell-side coverage as of early September 2026 clustered around a mean target near $10.71, with Wedbush at $13 and RBC at $9 while explicitly flagging speculative risk, which is a reasonable description of the spread of outcomes.

OCGN. Ocugen is pre-profit and pre-revenue, so traditional earnings metrics do not apply; what matters is cash runway versus burn. Management indicated a roughly $115 million convertible note offering would extend the runway into 2028 against projected operating expenses of about $50 to $60 million per year. Figures are approximate and tied to the asOf date; later raises or spending changes can move them materially.

Headline figures (approximate, September 2026): IRD shows market cap ~$580M after the September 9, 2026 move (~$480M before it), share price ~$7.00, a 52-week high, against a 52-week low of ~$1.32, revenue (ttm) ~$9.9M, almost entirely Viatris collaboration reimbursement, q2 2026 revenue ~$0.8M, down from ~$2.9M in Q2 2025; OCGN shows market capitalization ~$475 million (mid-2026), shares outstanding ~339 million, q1 2026 net loss ~$19.2 million, cash and restricted cash (mar 31, 2026) ~$32.2 million.

IRD and OCGN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined IRD and OCGN exposure against your real portfolio. It is not an investment adviser.